In a 45‑50‑year‑old patient with an unprovoked popliteal deep vein thrombosis, no personal or family history of thrombophilia, currently on warfarin for three months with a therapeutic INR of 2.5, what is the appropriate anticoagulation management?

Continue Warfarin for a Total of 6 Months (Option B)

For this 45-50 year-old patient with unprovoked popliteal DVT who is tolerating warfarin well with therapeutic INR, the appropriate management is to continue warfarin for a total duration of 6 months, then reassess for extended therapy based on bleeding risk.

Rationale Based on Guidelines

The FDA warfarin label explicitly states: "For patients with a first episode of idiopathic DVT or PE, warfarin is recommended for at least 6 to 12 months" 1. This directly addresses unprovoked (idiopathic) DVT and establishes the minimum treatment duration.

The 2012 ACCP guidelines reinforce this approach, recommending at least 3 months of anticoagulation for unprovoked proximal DVT, with evaluation after 3 months for extended therapy 2. For patients with low or moderate bleeding risk (which this patient appears to have given excellent tolerance and therapeutic INR of 2.5), they suggest extended anticoagulant therapy over stopping at 3 months (Grade 2B).

Why Not the Other Options?

Option A (Discontinue Now) - Incorrect

Stopping at 3 months is premature for unprovoked DVT. The 2012 ISTH guidance emphasizes that unprovoked VTE carries approximately 10% annual recurrence risk after stopping anticoagulation 3. The case-fatality rate of recurrent VTE (5%) must be weighed against bleeding risk 3.

Option C (Indefinite Therapy) - Premature Decision

While extended therapy may ultimately be appropriate, this decision should be made after completing the initial 6-month treatment course, not at 3 months 2. The 2020 ASH guidelines recommend reassessing after the primary treatment phase 4.

Option D (Thrombophilia Testing) - Not Indicated

Thrombophilia testing should not alter management in this scenario. The 2012 ACCP guidelines note that inherited thrombophilias do not change the recommendation for initial treatment duration 2. Testing is generally unhelpful for determining anticoagulation duration in unprovoked VTE 5.

Assessment of Bleeding Risk

This patient has favorable characteristics for low bleeding risk 3:

• Age under 70 years
• Therapeutic INR of 2.5 (target range 2.0-3.0)
• Tolerating warfarin "very well" with no bleeding episodes during initial 3 months
• No mention of high-risk medications (aspirin, NSAIDs, clopidogrel)
• Good INR control suggests compliance and understanding

Decision Algorithm After 6 Months

At the 6-month mark, reassess for extended therapy by evaluating:

1. Bleeding risk factors: Age, prior bleeding, comorbidities, concomitant antiplatelet agents
2. Quality of anticoagulation: Time in therapeutic range (should be >50%) 3
3. Patient preference: Tolerance for daily medication and monitoring
4. Optional risk stratification: D-dimer testing 3-4 weeks after stopping anticoagulation (low D-dimer = 4% annual recurrence vs high D-dimer = 9%) 3

If bleeding risk remains low and patient is willing, consider extended anticoagulation given the unprovoked nature of the DVT 2.

Common Pitfalls to Avoid

• Don't stop at 3 months for unprovoked proximal DVT - this is the minimum duration, not the target
• Don't order thrombophilia testing to guide duration - it won't change management
• Don't commit to indefinite therapy at 3 months - complete the initial 6-month course first
• Don't ignore the patient's excellent anticoagulation control - this favors extended therapy if needed